Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
Juan Miguel Mendoza, a director at Herbalife Ltd. (NYSE:HLF), recently acquired 5,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The purchase, made on May 2, 2025, was valued at approximately $33,650, with shares priced at $6.73 each - near the current trading price of $6.86. This acquisition brings Mendoza’s total direct ownership to 140,000 shares in the $696 million market cap company. According to InvestingPro analysis, Herbalife is currently trading below its Fair Value, with a notably low P/E ratio of 2.47.
Additionally, Mendoza received 21,857 restricted stock units (RSUs) under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These RSUs were granted at no cost and will fully vest on April 15, 2026, contingent upon Mendoza’s continued service on the company’s Board of Directors. Following these transactions, Mendoza’s total shareholding amounts to 161,857 shares. InvestingPro subscribers can access detailed insider trading analysis along with 8 additional ProTips about Herbalife’s financial health, which is rated as "GOOD" by their proprietary scoring system.
In other recent news, Herbalife reported its first-quarter earnings for 2025, showcasing a strong financial performance. The company exceeded earnings per share (EPS) expectations with $0.59, surpassing the forecasted $0.40, while revenue slightly missed projections at $1.22 billion against an anticipated $1.23 billion. Despite this revenue miss, Herbalife’s adjusted EBITDA grew by 19% year-over-year, indicating improved operational efficiency. The company has also revised its 2025 constant currency sales guidance to a range of 0.5% to 5.5% growth, alongside an increased EBITDA forecast of $625 million to $655 million.
Herbalife’s new distributor growth remained robust with a 16% year-over-year increase, although challenges persist in the North American market. The company has been actively working on strategic acquisitions, such as Protocol Health, Pruvit Ventures, and Link Biosciences, to bolster future growth prospects. These acquisitions are expected to enhance Herbalife’s product offerings and technology capabilities, aligning with its broader strategy and vision. Citi analyst Chasen Bender maintained a Buy rating on Herbalife’s stock, though the price target was adjusted to $11 from $13, reflecting mixed financial results and ongoing cost pressures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.